New generations of dihydropyridines for treatment of hypertension  

作　　者：Angela L Wang Costantino Iadecola Gang Wang 

机构地区：[1]Premed Program, Washington University in St. Louis, St. Louis, MO, USA [2]Feil Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA

出　　处：《Journal of Geriatric Cardiology》2017年第1期67-72,共6页老年心脏病学杂志（英文版）

摘　　要：Since the calcium channel blocker （CCB） has become one of the most prescribed agents for antihypertensive monotherapy in the world, this brief review will focus on the recent research and development of the dihydropyridine （DHP） CCB, addressing pharmacological mecha- nisms for the clinical efficacy of the third and fourth generations of the DHP CCBs, especially on their possible central mechanisms underlying lowering blood pressure.

关 键 词：Central nervous system Dihydropyridine HYPERTENSION Voltage-gated calcium channel blocker 

分 类 号：TQ463.54[化学工程—制药化工] TQ457.29